


**In the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-22 (Cancelled)

23. (Currently Amended) A method of treating a neovascular eye condition associated with angiogenesis in a human or animal comprising administering to said human or animal a pharmaceutically effective amount of EM-138,



~~or a hydrolysis product or a metabolite~~ an epoxide thereof or a hydrolysis product of an epoxide thereof.

24. (Previously Presented) The method of Claim 23, wherein the amount administered is between approximately 0.1 and approximately 330/mg/kg/day.

25. (Previously Presented) The method of Claim 24, wherein the amount administered is between approximately 0.5 and approximately 50 mg/kg/day.

26. (Previously Presented) The method of Claim 25, wherein the amount administered is between approximately 1 and approximately 10 mg/kg/day.

27. (Previously Presented) The method of Claim 23, wherein the compound is administered in the form of a tablet or capsule.

28. (Currently Amended) The method of Claim 23, wherein the compound is administered in the form of a lozenge, a capsule, a cachet, a tablet, a solution, a suspension, an emulsion, a bolus, a powder, a granule, an aerosol, a suppository, a spray, a pastille, an ointment, a cream, a paste, a foam, a gel, a ~~tampon~~ tampon or a pessary.

29. (Previously Presented) The method of Claim 23, wherein the administration is oral, parenteral, transdermal or topical.
30. (Previously Presented) The method of Claim 23, wherein the administration is bulingual, buccal, rectal, vaginal or nasal.
31. (Previously Presented) The method of Claim 23, wherein the eye condition is diabetic retinopathy.
32. (Previously Presented) The method of Claim 23, wherein the eye condition is retinopathy of prematurity.
33. (Previously Presented) The method of Claim 23, wherein the eye condition is corneal graft rejection.
34. (Previously Presented) The method of Claim 23, wherein the eye condition is neovascular glaucoma.
35. (Previously Presented) The method of Claim 23, wherein the eye condition is retrolental fibroplasias.
36. (Previously Presented) The method of Claim 23, wherein the eye condition is epidemic keratoconjunctivitis.
37. (Previously Presented) The method of Claim 23, wherein the eye condition is Vitamin A deficiency.
38. (Previously Presented) The method of Claim 23, wherein the eye condition is contact lens overwear.
39. (Previously Presented) The method of Claim 23, wherein the eye condition is atopic keratitis.
40. (Previously Presented) The method of Claim 23, wherein the eye condition is superior limbic keratitis.
41. (Previously Presented) The method of Claim 23, wherein the eye condition is pterygium keratitis sicca.

42. (Previously Presented) The method of Claim 23, wherein the eye condition is myopia.

43. (Previously Presented) The method of Claim 23, wherein the eye condition is Terrien's marginal degeneration.

44. (Previously Presented) The method of Claim 23, wherein the eye condition is marginal keratolysis.

45. (Previously Presented) The method of Claim 23, wherein the eye condition is radial keratotomy.

46. (Previously Presented) The method of Claim 23, wherein the eye condition is macular degeneration.

47. (Previously Presented) The method of Claim 23, wherein the eye condition is post-laser complications.

48. (Previously Presented) The method of Claim 23, wherein the eye condition is chronic retinal detachment.

49. (Previously Presented) The method of Claim 23, wherein the eye condition is optic pits.

50. (Previously Presented) The method of Claim 23, wherein the eye condition is hyperviscosity syndrome.

51. (Previously Presented) The method of Claim 23, wherein the eye condition is chronic uveitis.

52. (Previously Presented) The method of Claim 23, wherein the eye condition is chronic vitritis.

Claim 53. Cancelled.

54. (Previously Presented) The method of Claim 23, wherein the eye condition is age-related macular degeneration.

55. (Previously Presented) The method of Claim 23, wherein the eye condition is presumed ocular histoplasmosis.

56. (Previously Presented) The method of Claim 23, wherein the eye condition is an infection causing retinitis or choroiditis.

57. (Previously Presented) The method of Claim 23, wherein the eye condition is proliferative vitreoretinopathy.


58. (Previously Presented) The method of Claim 23, wherein the eye condition is scleritis.

59. (Previously Presented) The method of Claim 23, wherein the eye condition is Eales' disease.

60. (Previously Presented) The method of Claim 23, wherein the eye condition is Best's disease.

61. (Previously Presented) The method of Claim 23, wherein the eye condition is trachoma.

62. (Currently Amended) The method of treating a neovascular eye condition associated with angiogenesis in a human or animal comprising administering to said human or animal a pharmaceutically effective amount of a composition comprising EM-138,



~~or a hydrolysis product or a metabolite~~ an epoxide thereof or a hydrolysis product of an epoxide thereof.

63. (Previously Presented) The method of Claim 62, wherein the effective amount is between approximately 0.1 and approximately 300 mg/kg/day.

64. (Previously Presented) The method of Claim 62, wherein the effective amount is between approximately 0.5 and approximately 50 mg/kg/day.

65. (Previously Presented) The method of Claim 62, wherein the effective amount is between approximately 1 and approximately 10 mg/kg/day.

66. (Currently Amended) The method of Claim 62, wherein the composition is in the form of a tablet, capsule, a lozenge, a cachet, a solution, a suspension, an emulsion, a powder, a granule, an aerosol, a suppository, a spray, a pastille, an ointment, a cream, a paste, a foam, a gel, a ~~tampon~~ tampon, or a pessary.

67. (Previously Presented) The method of Claim 62, further comprising an additive selected from an anti-oxidant, a buffer, a bacteriostat, a solute which renders the composition isotonic with the blood of the human or the animal, a suspending agent, a thickening agent, a flavoring agent, a gelatin, glycerine, a diluent, or any combination thereof.

68. (Previously Presented) The composition of Claim 62, further comprising a biodegradable polymer.